posted on 2016-12-13, 09:18authored byJ. K. Harrison, V. Van Der Wardt, Simon Paul Conroy, D. J. Stott, T. Dening, A. L. Gordon, P. Logan, T. J. Welsh, J. Taggar, R. Harwood, J. R. F. Gladman
The optimal management of hypertension in people with dementia is uncertain. This review explores if people with dementia experience greater adverse effects from antihypertensive medications, if cognitive function is protected or worsened by controlling blood pressure (BP) and if there are subgroups of people with dementia for whom antihypertensive therapy is more likely to be harmful. Robust evidence is scant, trials of antihypertensive medications have generally excluded those with dementia. Observational data show changes in risk association over the life course, with high BP being a risk factor for cognitive decline in mid-life, while low BP is predictive in later life. It is therefore possible that excessive BP lowering in older people with dementia might harm cognition. From the existing literature, there is no direct evidence of benefit or harm from treating hypertension in people with dementia. So what practical steps can the clinician take? Assess capacity, establish patient preferences when making treatment decisions, use ambulatory monitoring to thoroughly assess BP, individualise and consider deprescribing where side effects (e.g. hypotension) outweigh the benefits. Future research might include pragmatic randomised trials of targeted deprescribing, which include patient-centred outcome measures to help support decision-making and studies to address mechanistic uncertainties.
Funding
This article arose from the HIND (Hypertension in
Dementia) programme, which has been supported by a
start-up grant from the British Geriatrics Society (BGS) and
the National Institute for Health Research—Research for
J. K. Harrison et al.
744
at University of Leicester on December 13, 2016 http://ageing.oxfordjournals.org/ Downloaded from
Patient Benefit Programme (PB-PG-1112-29070). The views
expressed are those of the authors and not necessarily those
of the BGS, NHS, the NIHR or the Department of Health.
J.K.H. is supported by a clinical research fellowship from
Alzheimer Scotland and The University of Edinburgh Centre
for Cognitive Ageing and Cognitive Epidemiology, part of
the cross council Lifelong Health and Wellbeing Initiative
(MR/L501530/1). Funding from the Biotechnology and
Biological Sciences Research Council (BBSRC) and Medical
Research Council (MRC) is gratefully acknowledged.
History
Citation
Age and Ageing 2016; 45: 740–746
Author affiliation
/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Health Sciences
Version
AM (Accepted Manuscript)
Published in
Age and Ageing 2016; 45: 740–746
Publisher
Oxford University Press (OUP) for British Geriatrics Society